company background image
ZYNE logo

Zynerba Pharmaceuticals NasdaqCM:ZYNE Stock Report

Last Price

US$1.30

Market Cap

US$65.6m

7D

4.0%

1Y

96.1%

Updated

12 Oct, 2023

Data

Company Financials +

Zynerba Pharmaceuticals, Inc.

NasdaqCM:ZYNE Stock Report

Market Cap: US$65.6m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

My Notes

Capture your thoughts, links and company narrative

Zynerba Pharmaceuticals, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Zynerba Pharmaceuticals
Historical stock prices
Current Share PriceUS$1.30
52 Week HighUS$1.40
52 Week LowUS$0.25
Beta1.19
1 Month Change-1.52%
3 Month Change282.24%
1 Year Change96.08%
3 Year Change-65.79%
5 Year Change-82.17%
Change since IPO-92.00%

Recent News & Updates

Recent updates

Is Zynerba Pharmaceuticals (NASDAQ:ZYNE) In A Good Position To Deliver On Growth Plans?

Mar 01
Is Zynerba Pharmaceuticals (NASDAQ:ZYNE) In A Good Position To Deliver On Growth Plans?

Is Zynerba Pharmaceuticals (NASDAQ:ZYNE) In A Good Position To Invest In Growth?

Nov 11
Is Zynerba Pharmaceuticals (NASDAQ:ZYNE) In A Good Position To Invest In Growth?

Zynerba stock rises on US patent for cannabidiol Zygel's use for Fragile X syndrome

Oct 06

Zynerba Pharmaceuticals GAAP EPS of -$0.24 misses by $0.01

Aug 10

We Think Zynerba Pharmaceuticals (NASDAQ:ZYNE) Can Afford To Drive Business Growth

Jul 22
We Think Zynerba Pharmaceuticals (NASDAQ:ZYNE) Can Afford To Drive Business Growth

Zynerba inks equity funding contract of up to $20M with Lincoln Park Capital

Jul 21

Here's Why We're Watching Zynerba Pharmaceuticals' (NASDAQ:ZYNE) Cash Burn Situation

Mar 23
Here's Why We're Watching Zynerba Pharmaceuticals' (NASDAQ:ZYNE) Cash Burn Situation

We Think Zynerba Pharmaceuticals (NASDAQ:ZYNE) Can Afford To Drive Business Growth

Dec 02
We Think Zynerba Pharmaceuticals (NASDAQ:ZYNE) Can Afford To Drive Business Growth

We Think Zynerba Pharmaceuticals (NASDAQ:ZYNE) Can Afford To Drive Business Growth

May 27
We Think Zynerba Pharmaceuticals (NASDAQ:ZYNE) Can Afford To Drive Business Growth

Zynerba Pharma shares slip 10% on Zygel update in Fragile X syndrome

Dec 17

Is Zynerba Pharmaceuticals (NASDAQ:ZYNE) In A Good Position To Invest In Growth?

Nov 23
Is Zynerba Pharmaceuticals (NASDAQ:ZYNE) In A Good Position To Invest In Growth?

Zynerba Pharmaceuticals EPS beats by $0.12

Nov 09

Zynerba Zygel Remains A Huge Part Of The Company's Pipeline Despite Setback

Oct 29

Shareholder Returns

ZYNEUS PharmaceuticalsUS Market
7D4.0%1.2%-0.3%
1Y96.1%1.1%20.4%

Return vs Industry: ZYNE exceeded the US Pharmaceuticals industry which returned 2.3% over the past year.

Return vs Market: ZYNE exceeded the US Market which returned 21.3% over the past year.

Price Volatility

Is ZYNE's price volatile compared to industry and market?
ZYNE volatility
ZYNE Average Weekly Movement84.2%
Pharmaceuticals Industry Average Movement10.4%
Market Average Movement6.0%
10% most volatile stocks in US Market18.5%
10% least volatile stocks in US Market3.0%

Stable Share Price: ZYNE's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: ZYNE's weekly volatility has increased from 43% to 84% over the past year.

About the Company

FoundedEmployeesCEOWebsite
200726Armando Anidowww.zynerba.com

Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing pharmaceutically produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It is developing Zygel, a pharmaceutically produced cannabidiol formulated as a permeation-enhanced gel for transdermal delivery.

Zynerba Pharmaceuticals, Inc. Fundamentals Summary

How do Zynerba Pharmaceuticals's earnings and revenue compare to its market cap?
ZYNE fundamental statistics
Market capUS$65.60m
Earnings (TTM)-US$37.58m
Revenue (TTM)n/a

0.0x

P/S Ratio

-1.7x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ZYNE income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$37.58m
Earnings-US$37.58m

Last Reported Earnings

Jun 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-0.74
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did ZYNE perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2023/10/12 07:11
End of Day Share Price 2023/10/10 00:00
Earnings2023/06/30
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Zynerba Pharmaceuticals, Inc. is covered by 13 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Corey DavisCanaccord Genuity
Elemer PirosCantor Fitzgerald & Co.
Oren LivnatH.C. Wainwright & Co.